No Data
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $32
Promising Efficacy and Long-term Response of Iovance Biotherapeutics' Lifileucel in NSCLC: A Buy Recommendation
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $22
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Daily options tracking | Included in the Dow Jones component stocks! Nvidia rose 2% most profitable with call options doubling in a single day; "Audit Scandal" unfinished, super micro computer put options skyrocketing for consecutive days.
Amazon's performance surged by 6% after the earnings report, with large investors betting on selling put options and being bullish. The largest single transaction involved $2.7 million; China's large cap stock ETF experienced a sharp increase in implied volatility levels, as the market awaits the expected outcome.
Iovance Biotherapeutics (NASDAQ:IOVA) Delivers Shareholders Solid 166% Return Over 1 Year, Surging 4.9% in the Last Week Alone